Bilinsky Igor's Insider Trades & SAST Disclosures
Bilinsky Igor's most recent trade in Iovance Biotherapeutics Inc was a trade of 93,750 Restricted Stock Units done . Disclosure was reported to the exchange on March 5, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Bilinsky Igor.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Mar 2025 | 93,750 | 93,750 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 62,106 | 120,880 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 58,590 | 70,317 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.04 per share. | 03 Mar 2025 | 33,302 | 87,578 (0%) | 0% | 4.0 | 134,540 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Mar 2025 | 3,516 | 14,065 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,813 | 60,352 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jan 2025 | 2,813 | 0 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.89 per share. | 14 Jan 2025 | 1,578 | 58,774 (0%) | 0% | 5.9 | 9,294 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,516 | 59,323 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2024 | 3,516 | 17,581 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 02 Dec 2024 | 1,784 | 57,539 (0%) | 0% | 9.1 | 16,181 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 2,813 | 2,813 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Oct 2024 | 2,813 | 57,235 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.77 per share. | 14 Oct 2024 | 1,428 | 55,807 (0%) | 0% | 9.8 | 13,952 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 23,437 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 23,438 | 66,313 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 11,891 | 54,422 (0%) | 0% | 10.8 | 129,017 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,516 | 44,659 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Sep 2024 | 3,516 | 21,097 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.85 per share. | 03 Sep 2024 | 1,784 | 42,875 (0%) | 0% | 10.8 | 19,356 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,813 | 42,571 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jul 2024 | 2,813 | 5,626 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.68 per share. | 15 Jul 2024 | 1,428 | 41,143 (0%) | 0% | 8.7 | 12,395 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,516 | 41,542 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 3,516 | 24,613 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 03 Jun 2024 | 1,784 | 39,758 (0%) | 0% | 8.4 | 14,932 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 2,812 | 39,453 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2024 | 2,812 | 8,439 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 11.89 per share. | 15 Apr 2024 | 1,427 | 38,026 (0%) | 0% | 11.9 | 16,967 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 14,061 | 43,928 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Mar 2024 | 14,061 | 28,129 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.96 per share. | 04 Mar 2024 | 7,287 | 36,641 (0%) | 0% | 17.0 | 123,588 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 105,470 | 105,470 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 46,875 | 46,875 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Bilinsky Igor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,813 | 31,444 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Bilinsky Igor | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jan 2024 | 2,813 | 11,251 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Bilinsky Igor | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.37 per share. | 16 Jan 2024 | 1,577 | 29,867 (0%) | 0% | 8.4 | 13,199 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 2,813 | 28,608 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jul 2023 | 2,813 | 16,877 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.76 per share. | 14 Jul 2023 | 1,395 | 27,213 (0%) | 0% | 7.8 | 10,825 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 2,812 | 19,690 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2023 | 2,812 | 27,190 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.64 per share. | 14 Apr 2023 | 1,395 | 25,795 (0%) | 0% | 5.6 | 7,868 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 84,380 | 84,380 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 42,190 | 42,190 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 11,248 | 22,502 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jan 2023 | 11,248 | 29,049 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.43 per share. | 17 Jan 2023 | 4,671 | 24,378 (0%) | 0% | 6.4 | 30,035 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 18,850 | 0 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 18,850 | 28,354 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.11 per share. | 03 Jan 2023 | 10,553 | 17,801 (0%) | 0% | 6.1 | 64,479 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 18,850 | 18,850 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2022 | 18,850 | 18,850 (0%) | 0% | 0 | Common Stock | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.73 per share. | 14 Jun 2022 | 9,346 | 9,504 (0%) | 0% | 7.7 | 72,245 | Common Stock |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 67,500 | 67,500 | - | - | Stock Option (right to buy) | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jan 2022 | 33,750 | 33,750 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2021 | 37,700 | 37,700 | - | - | Restricted Stock Units | |
| Iovance Biotherapeutics Inc | Igor Bilinsky | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2021 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Oncternal Therapeutics Inc | Igor Bilinsky | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 130,000 | 130,000 | - | - | Stock Option |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges